Sunshine Biopharma (SBFM) Research & Development (2011 - 2026)
Sunshine Biopharma's (SBFM) quarterly Research & Development came in at $31724.0 in Q1 2026, down 85.26% YoY from $215277.0 in Q1 2025, and down 56.84% on a QoQ basis from $73501.0 in Q4 2025.
Sunshine Biopharma (SBFM) Research & Development (2011 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has 14 years of Research & Development data on file, last reported at $31724.0 in Q1 2026.
- Quarterly Research & Development fell 85.26% year-over-year to $31724.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $420755.0 (down 54.62% YoY) and the FY2025 annual result came in at $604308.0, down 35.29% from the prior year.
- Research & Development declined to $31724.0 in Q1 2026, from $73501.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $816328.0 in Q4 2023 to a low of $31724.0 in Q1 2026.
- A 5-year average of $249271.9 and a median of $215277.0 in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development soared 1854.67% — and 2026, when it slumped 85.26%.
- Tracing SBFM's Research & Development over 5 years: stood at $41763.0 in 2022, then soared by 1854.67% to $816328.0 in 2023, then slumped by 81.71% to $149272.0 in 2024, then sank by 50.76% to $73501.0 in 2025, then tumbled by 56.84% to $31724.0 in 2026.
- The last three Research & Development figures came in at $31724.0 (Q1 2026), $73501.0 (Q4 2025), and $119298.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Sunshine Biopharma | 1.54 Mn | -12.21 Mn | 2.43 Mn | 13,222.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13,222.00 |
| Mar 31, 2026 | 31,724.00 |
| Dec 31, 2025 | 73,501.00 |
| Sep 30, 2025 | 119,298.00 |
| Jun 30, 2025 | 196,232.00 |
| Mar 31, 2025 | 215,277.00 |
| Dec 31, 2024 | 149,272.00 |
| Sep 30, 2024 | 126,362.00 |
| Jun 30, 2024 | 436,235.00 |
| Mar 31, 2024 | 222,033.00 |
| Dec 31, 2023 | 816,328.00 |
| Sep 30, 2023 | 238,012.00 |
| Jun 30, 2023 | 368,565.00 |
| Mar 31, 2023 | 432,925.00 |
| Dec 31, 2022 | 41,763.00 |
| Sep 30, 2022 | 362,500.00 |
| Jun 30, 2022 | 45,943.00 |
| Mar 31, 2022 | 361,652.00 |
| Dec 31, 2021 | 91,198.00 |
| Sep 30, 2021 | 222,465.00 |